Working...
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 8 of 137 for:    "Connective Tissue Disease" | "Abatacept"

Abatacept for SLE Arthritis (IM101-330)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT02429934
Recruitment Status : Recruiting
First Posted : April 29, 2015
Last Update Posted : April 18, 2019
Sponsor:
Collaborator:
Bristol-Myers Squibb
Information provided by (Responsible Party):
Bevra Hahn, MD, University of California, Los Angeles

Tracking Information
First Submitted Date  ICMJE April 24, 2015
First Posted Date  ICMJE April 29, 2015
Last Update Posted Date April 18, 2019
Study Start Date  ICMJE October 2015
Estimated Primary Completion Date August 1, 2019   (Final data collection date for primary outcome measure)
Current Primary Outcome Measures  ICMJE
 (submitted: April 28, 2015)
Baseline to 16 week comparison of at least a 20% improvement in Tender and Swollen 28 joint count over the 16 weeks period [ Time Frame: Week 16 ]
Comparing dichotomous results for tender and swollen joints for those who improved and those who did not improve by at least 20%
Original Primary Outcome Measures  ICMJE Same as current
Change History Complete list of historical versions of study NCT02429934 on ClinicalTrials.gov Archive Site
Current Secondary Outcome Measures  ICMJE
 (submitted: April 28, 2015)
  • Baseline to 16 week comparison of SLEDAI 2K improvement between patients in two study arms [ Time Frame: 16 weeks ]
    Change of 3 points in SLEDAI 2K is considered an improvement
  • Baseline to 16 week comparison of change in the PGA score between patients in two study arms [ Time Frame: 16 weeks ]
    A change of 0.8 points on a 3 point scale or less is considered as stable
  • Longitudinal changes in CDAI between patients in two study arms [ Time Frame: measured at baseline, 8, 12 and 16 weeks ]
    Comparing means and medians over the length of the study
  • Baseline to 16 week comparison of changes in the synovitis, tenosynovitis and erosions scores measured by ultrasound between patients in two study arms [ Time Frame: 16 weeks ]
  • Baseline to 16 week comparison of changes in the FACIT fatigue score between patients in two study arms [ Time Frame: 16 weeks ]
  • Baseline to 16 week comparison of changes in the SF 36 quality of life score between patients in two study arms [ Time Frame: 16 weeks ]
  • Difference in the number of AEs and SAEs between patients in two study arms [ Time Frame: 16 weeks ]
    Will compare total number of AEs and total number of SAEs as well as those AEs/SAEs which may be related to the study drug
  • Longitudinal changes in the total number of tender and swollen joints between patients in two study arms [ Time Frame: baseline, 4, 8, 12 and 16 weeks ]
  • Baseline to 16 week change in peripheral blood T cell compartments between patients in two study arms [ Time Frame: 16 weeks ]
  • Longitudinal change in anti-DNA and total IgG levels as well as Serum complement levels between patients in two study arms [ Time Frame: Baseline 8 and 16 weeks ]
  • Longitudinal change in serum levels of BAFF between patients in two study arms [ Time Frame: Baseline, 8 and 16 weeks ]
  • Time to response of 20% improvement in joint counts between patients in two study arms [ Time Frame: baseline, 4, 8, 12 and 16 weeks ]
  • Comparing baseline to 16 week improvement for the total sum score of tender and swollen joints between the two study arms [ Time Frame: 16 weeks ]
    Changes in Means and Medians will be used as the point of comparison
  • Comparing the proportion of patients who are able to taper prednisone to <10mg/day by week 16 between the two study arms [ Time Frame: 16 weeks ]
    This analysis is for the subset of patients who start the study taking 10 to 20mg of prednisone per day
Original Secondary Outcome Measures  ICMJE Same as current
Current Other Pre-specified Outcome Measures Not Provided
Original Other Pre-specified Outcome Measures Not Provided
 
Descriptive Information
Brief Title  ICMJE Abatacept for SLE Arthritis (IM101-330)
Official Title  ICMJE Efficacy of Abatacept in Inflammatory Polyarthritis of Systemic Lupus Erythematosus (SLE)
Brief Summary

This research trial is for patients who have been diagnosed with systemic lupus erythematosus (SLE) with swollen, tender joints (which is called inflammatory polyarthritis) because of the SLE.

The purpose of this clinical research study is to evaluate the safety and effectiveness of treatment with abatacept (Abatacept) 125mg injected subcutaneously (under the skin) weekly for 16 weeks versus placebo injections(a substance with no active ingredients and therefore may have no treatment benefit) in subjects with SLE and inflammatory polyarthritis. The effectiveness will be assessed primarily by the number of swollen, tender joints (called a joint count) at each of study visits.

Study Medication Abatacept is approved in the U.S. for treating rheumatoid arthritis by prescription and has not been approved by the U.S. Food and Drug Administration for treating SLE yet.

In this study, subjects will receive treatment with either abatacept or placebo once a week for 16 weeks (a total of 16 injections).

Detailed Description Not Provided
Study Type  ICMJE Interventional
Study Phase  ICMJE Phase 1
Phase 2
Study Design  ICMJE Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Condition  ICMJE Systemic Lupus Erythematosus Arthritis
Intervention  ICMJE
  • Drug: abatacept
    125mg injected subcutaneously weekly for 16 weeks
    Other Name: Orencia
  • Drug: Placebo
Study Arms  ICMJE
  • Active Comparator: Abatacept
    32 SLE patients to be treated with subcutaneous abatacept 125mg sq once a week for 16 weeks.
    Intervention: Drug: abatacept
  • Placebo Comparator: Placebo
    32 SLE patients to be treated with subcutaneous placebo once a week for 16 weeks.
    Intervention: Drug: Placebo
Publications * Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status  ICMJE Recruiting
Estimated Enrollment  ICMJE
 (submitted: April 28, 2015)
64
Original Estimated Enrollment  ICMJE Same as current
Estimated Study Completion Date  ICMJE December 31, 2019
Estimated Primary Completion Date August 1, 2019   (Final data collection date for primary outcome measure)
Eligibility Criteria  ICMJE

Inclusion Criteria:

  1. Meet at least 4 of the 11 American College of Rheumatology (ACR) 1997 criteria for classification of SLE (see Appendix 1).OR meet the recent classification recommended by SLICC (Appendix 2) 6
  2. ≥3 swollen and tender joints on 2 examinations at least 2 weeks apart and no more than 8 weeks apart.
  3. SLEDAI2K score ≥4 indicating active disease.
  4. Documented positive ANA (≥1:80) and/or anti-dsDNA during course of SLE.
  5. Men and women, at least 18 years of age. Women of childbearing potential must use adequate method(s) of contraception to avoid pregnancy throughout the study and for up to 2 months after last study drug dose. They must have a negative serum or urine pregnancy test prior to the start of study medication.
  6. Background therapies allowed: antimalarials (dose constant for ≥ one month before study entry and during 16 weeks of trial), methotrexate (same criteria as for antimalarials), azathioprine (same criteria), mycophenolate (same criteria), leflunomide (same criteria).

During the screening period and for up to 6 weeks after randomization, a daily prednisone (or equivalent) regimen of up to 20 mg daily may be initiated to treat the moderate to severe disease activity present at screening. The initial steroid regimen is not required if investigators or patients believe that the risks would outweigh the potential benefits. Patients who do not take any glucocorticoids during the study will be included in the treatment groups and analysis.

*Steroids should be tapered to a target dose of no more than 10 mg/day of prednisone (or equivalent) by the end of Week 8 (Day 56). The steroid regimen should be tapered as quickly as safely possible. Prednisone dose requirements higher than 10 mg daily at the 8 week visit will cause the patient to be ruled a non-responder for the abatacept treatment arm.

Exclusion Criteria:

  1. Subjects with active infection requiring oral or IV antibiotics within one month of first dose of study medication.
  2. Subjects with BILAG A in any system outside the musculoskeletal system.
  3. Subjects with positive quantiferon Gold test in the absence of treatment for tuberculosis.
  4. Subjects with positive tests for active infection with hepatitis B or C during the past 6 months. Any confirmed positive test for HIV at any time prior to entry into this study.
  5. Subjects with active glomerulonephritis (>3 g protein/24h and/or active urine sediment).
  6. Subjects with active CNS disease.
  7. Subjects with any other serious disease that would require immunosuppressive or parenteral anti-microbial therapy outside the study protocol.
  8. Inability to self-administer subcutaneous injections, to comply with instructions, or to keep appointments for study visits.
  9. Treatment with rituximab within the past 6 months (B cells must be detectable in peripheral blood at onset of treatment with study biologic), belimumab within the past 5 months, cyclophosphamide within the past 3 months.
  10. Treatment with any other immunomodulatory biologic or cyclophosphamide during treatment with abatacept is not allowed.
  11. Patients requiring >20 mg of prednisone daily.
  12. Women who are pregnant or breast feeding.
  13. Women of child bearing potential unwilling or unable to use an acceptable method to avoid pregnancy for the entire study period and for up to 2 months after last study drug.
  14. Subjects with a history of cancer within the last five years (other than non-melanoma skin cell cancers cured by local resection).
  15. Any laboratory test results that, in the opinion of the Investigator, might place the subject at unacceptable risk for participation in this study.
Sex/Gender  ICMJE
Sexes Eligible for Study: All
Ages  ICMJE 18 Years and older   (Adult, Older Adult)
Accepts Healthy Volunteers  ICMJE No
Contacts  ICMJE
Contact: Bevra Hahn, M.D. 310-825-7991 bhahn@mednet.ucla.edu
Contact: Bal-lan Yen (310) 206-4112 byen@mednet.ucla.edu
Listed Location Countries  ICMJE United States
Removed Location Countries  
 
Administrative Information
NCT Number  ICMJE NCT02429934
Other Study ID Numbers  ICMJE IM101-330 SLE Arthritis
Has Data Monitoring Committee Yes
U.S. FDA-regulated Product Not Provided
IPD Sharing Statement  ICMJE Not Provided
Responsible Party Bevra Hahn, MD, University of California, Los Angeles
Study Sponsor  ICMJE University of California, Los Angeles
Collaborators  ICMJE Bristol-Myers Squibb
Investigators  ICMJE
Principal Investigator: Bevra Hahn, M.D. University of California, Los Angeles
PRS Account University of California, Los Angeles
Verification Date April 2019

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP